Agios Pharma (NASDAQ:AGIO) reported Q2 EPS of ($1.68), $0.07 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.76 million.
Agios Pharma (NASDAQ:AGIO) reported Q2 EPS of ($1.68), $0.07 better than the analyst estimate of ($1.75). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $2.76 million.